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Sarcopenia is an age-related clinical condition characterized by the progressive loss of motor units and wasting of muscle fibers
resulting in decreased muscle function. The molecular mechanisms leading to sarcopenia are not completely identified, but the
increased oxidative damage occurring in muscle cells during the course of aging represents one of the most accepted underlying
pathways. In fact, skeletal muscle is a highly oxygenated tissue and the generation of reactive oxygen species is particularly enhanced
in both contracting and at rest conditions. It has been suggested that oral antioxidant supplementation may contribute at reducing
indices of oxidative stress both in animal and human models by reinforcing the natural endogenous defenses. Aim of the present
paper is to discuss present evidence related to possible benefits of oral antioxidants in the prevention and treatment of sarcopenia.
1. Introduction
There is a common and diﬀuse false myth that aging
is synonym of deterioration, pathology, and death. The
increased life expectancy in developed and developing coun-
tries is parallel to the need to identify interventions able
to preserve health and function even at older age, delaying
the physical and cognitive declines. Aging is an extremely
complex multifactorial process characterized by progressive
physiological, genetic, and molecular changes, responsible
for the increase risk of morbidity and death [1]. Several
hypotheses [2, 3] have been proposed to explain this inborn
process common to all living beings, but one of the most
plausible and better-accepted currently is the so-called “free
radical theory of aging.”
The age-associated loss of skeletal muscle mass and
strength (i.e., sarcopenia) seems an unavoidable part of the
aging process. After about the age of 50 years, there is a pro-
gressive decrease of muscle mass at the rate of 1-2% per year.
Similarly but with diﬀerent decline rate and timing, muscle
strength also decreases by about 3% yearly after 60 years of
age [4]. Sarcopenia is a multidimensional phenomenon of
aging (someone indicates it as a syndrome) and represents
a powerful risk factor for the development of negative health-
related events in the elderly. In fact, the relationships of
sarcopenia with impaired physical performance, frailty, loss
of functional independence, and increased risk of falls are
all well established in the literature [5]. Moreover, decreased
muscle strength is also highly predictive of incident disability
and all-cause mortality in older persons [6].
Oxidative damage has been proposed as one of the
major contributors of the skeletal muscle decline occurring
with aging [7, 8]. The identification of free radicals as
promoters of the aging process may imply that their inhi-
bition might limit the detrimental modifications they exert
on our organism (and, in particular, on skeletal muscle).
In other words, if molecules with antioxidant capacities
can counteract the oxidative damage, they may also play a
key role in preventing the onset of age-related conditions,
including the disabling process [9]. It will come to be true
that oxidative damage is at the basis of the pathophysiological
mechanisms responsible for sarcopenia (and other geriatric
conditions), and interventions aimed at enhancing the
endogenous antioxidant defenses (e.g., dietary antioxidant
supplementation) may gain special interest.
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The purpose of the present paper is to discuss current
available evidence about the eﬀects of antioxidant supple-
mentation on sarcopenia. Special attention will be obviously
given to studies focused on models of aging and involving
older participants.
2. The Free Radical Theory of Aging
This theory was formulated for the first time by Harman in
1956 [10]. He proposed that aging and the associated degen-
erative diseases were consequences of free radical-induced
damages to cells and the inability of counterbalancing
these changes by endogenous antioxidant defenses. Harman
initially explained the production of free radicals through
reactions involving molecular oxygen catalyzed in cells by
oxidative enzymes and subsequently postulated that genetic
and environmental factors might modify this process. In
1972, he then revised his theory identifying themitochondria
as primarily responsible for the physiological process of
aging [11]. Since oxidative damage is higher in cells and
structures with higher consumption of oxygen, he suggested
that mitochondria (consuming most of the intracellular
oxygen) were particularly exposed to oxidative damage
and potentially aﬀected lifespan. Miquel and colleagues
[12] subsequently confirmed such theory by recognizing
mitochondria as major actors of cellular aging. More recently
and consistently with these concepts, the free radical theory
of aging has been switched into a “mitochondrial free radical
theory of aging” [13].
Free radicals are a highly reactive chemical species with
a single unpaired electron in its outer orbit seeking to pair
with another free electron [14]. In particular, reactive oxygen
species (ROS), deriving from oxidative metabolism, have
higher reactivity than O2. ROS are constantly generated in
cells of aerobic organisms by the addition of a single electron
to the oxygen molecule with subsequently damage of biolog-
ical macromolecules (like lipids, proteins, and nucleic acids).
The interaction of ROS with normal cellular structures leads
to potentially nonreversible modifications, with consequent
cellular loss of function and death [3, 15, 16].
There are numerous sites of oxidant generation [17].
Mitochondrial electron transport, peroxisomal fatty acid,
cytochrome P-450, and phagocytic cells (the “respiratory
burst”) represent the most important ones. In particular,
the main source of ROS (estimated at approximately 90%
of the generated total) is located at the inner mitochondrial
membrane where oxidative phosphorylation takes place
[18]. Moreover, a variety of exogenous stimuli, such as
exposure to infections [19], radiations [20], xenobiotics
[21], environmental toxins [22], and ultraviolet light [23],
may also increase the ROS production in vivo. Interestingly,
mitochondria are both producers as well as targets of ROS.
In all organisms living in an aerobic environment,
ROS play an important role in the maintenance of body
homeostasis [24]. Recent studies [25, 26] have even shown
that ROS may function as an additional class of cellular mes-
sengers, being involved as physiological regulators of intra-
cellular signaling pathways (e.g., response to growth factor
stimulation or generation of the inflammatory response to
bacterial defense). Therefore, since free radicals are necessary
for correct functioning of the human organism, eﬃcient
mechanisms of antioxidant defense had to be developed
(especially in cells highly exposed to oxidation processes)
with the aim of protecting cellular constituents. Endogenous
antioxidants are present under diverse and numerous forms,
like enzymes (e.g., superoxide dismutase, catalase, glu-
tathione peroxidase, glutathione reductase), vitamins (e.g.,
vitamin C, vitamin E), and elements (e.g., selenium, zinc).
All these substances are able to neutralize ROS and protect
cells from free radical damage. Nevertheless, in a normal
scenario, about 1% of ROS is still able to avoid the control
of the antioxidant system, causing oxidation of surround-
ing tissues [27]. Moreover, oxidative damage is obviously
enhanced when the ROS production increases and/or the
antioxidant status decreases. According to the cellular con-
stituents attacked by the oxidative stress, lipid peroxidation
[28], protein oxidation [29], and DNA damage [30] will all
promote abnormalities of the cell structures incompatible
with proper cell function, leading to its death. Such cellular
loss has been finally indicated as being responsible for the
age-related degenerative diseases and conditions [31].
In summary, according to the free radical theory of aging,
oxidative damage is due to a redox imbalance between ROS
and the counteracting antioxidant forces generating a vicious
cycle responsible for the progressive augmentation of damage
[13]. The equilibrium between ROS production, antioxidant
defenses, and the cellular structures determines whether a
cell exposed to ROS increase will be destined to survival or
death [32].
3. The Antioxidant Defense System
Antioxidants are substances able to inhibit the rate of
oxidation [33, 34]. Mainly, antioxidant enzymes (e.g., cata-
lase, superoxide dismutase (SOD), glutathione peroxidase,
glutathione reductase) work to maintain a state of balance
preventing the transformation of ROS and to convert
them into more stable molecules (like water and molecular
oxygen). SOD exists in two forms: Cu/ZnSOD is present
in the cytoplasm of the eukaryotic cells whilst MnSOD is
located primarily in the mitochondria. Diﬀerently, endoge-
nous nonenzymatic elements with antioxidant properties
contribute to the maintenance of homeostasis by primarily
acting as cofactors for the antioxidant enzymes. A major
source of antioxidants is diet [35]. Among dietary antiox-
idants, the most important (and also largely available as
supplements) are vitamin C, vitamin E, and carotenoids.
Vitamin C acts as an antioxidant by inhibiting oxidation.
For example, ascorbic acid concentrations are inversely
associated with isoprostanes, a marker of lipid peroxidation
[36]. Vitamin C is involved in the regeneration of vitamin E
in lipoproteins and membranes. In fact, vitamin C reduces
the vitamin E radicals generated in cellular membranes
and inhibits the propagation of α-tocopheroxyl radical. It
is the most important hydrophilic antioxidant [27, 37, 38].
Conversely, vitamin E is the most important lipophilic
antioxidant. It has been reported a significantly high corre-
lation of α-tocopherol (the most diﬀuse form of circulating
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vitamin E) with physical performance and of γ-tocopherol
with skeletal muscle strength [9]. Nunes and colleagues [39]
demonstrated that a vitamin-E-deficient diet may cause an
increased caspase-like activation (a proapoptotic stimulus)
in animal model. Consistently, vitamin E is inversely corre-
lated with lipid peroxidation and positively correlated with
in cytochrome oxidase activity (causing a mitochondrial
respiratory chain dysfunction) [40].
The supplementation of diﬀerent antioxidants will
provide diﬀerent eﬀects on oxidation according to the
hydrophobicity of the administered molecule. In fact, fat-
soluble antioxidants (e.g., vitamin E) are particularly eﬀec-
tive at inhibiting lipoprotein peroxidation, whereas water-
soluble antioxidants (e.g., vitamin C)more eﬃciently protect
the aqueous phase. However, these antioxidants do not only
act individually, but also cooperatively and sometimes even
synergistically. Moreover, their radical-scavenging eﬀects
depend on various factors, the site of generation of the
oxidant and the localization of the antioxidant [41, 42].
Another important source of antioxidants is assured by
dietary carotenoids (including α-carotene, β-carotene, β-
cryptoxanthin, lutein, zeaxanthin, and lycopene). Caroten-
oids are lipid soluble molecules that interact with the lipid
membrane bilayer [43]. They scavenge free radicals, quench
singlet oxygen, inhibit lipid peroxidation, and modulate
redox-sensitive transcription factors (e.g., the nuclear factor
kappa-light-chain-enhancer of activated B cells or NF-κB)
that are involved in the upregulation of proinflammatory
cytokines [44, 45]. Upritchard and colleagues [46] have
reported that the supplementation of carotenoids may signif-
icantly improve antioxidant status and reduce concentrations
of isoprostanes.
Numerous foods like fruits, nuts, vegetables, and spices
are rich in antioxidants. Blueberries, cranberries, blackber-
ries, plums, apples, cherries, and prunes are fruits particu-
larly rich in antioxidants. Red and black beans, artichokes,
and russet potatoes are the vegetables with highest content of
antioxidants. Ground cloves, cinnamon, and oregano con-
tain the greatest amount of antioxidants among spices [47].
Finally, it is worth to be mentioned that the antioxidant
system function is highly influenced by age [32, 48]. In fact,
with aging, there is a progressive decline in mitochondrial
function and increase in oxidative damage. ROS overwhelms
the endogenous antioxidant defense system during the aging
process, causing harmful modifications of myofiber cellular
proteins, lipids, and DNA. Moreover, the antioxidant dietary
intake may easily decrease for multiple reasons (e.g., mobility
disability leading to inadequate food supply; lack of social
support; oral problems leading to repetitive and inadequate
diets, etc.). Thus, it is not surprising that poor antioxidant
status is commonly found at the foundations of several
conditions of older age [49].
4. Sarcopenia
In 1989, Rosenberg coined the term “sarcopenia” (from
Greek: σαρξ or flesh and πενι´α or loss) to describe the
progressive and involuntary loss of skeletal muscle mass
and function occurring with aging [50]. Although it is
diﬃcult to provide an exact prevalence of sarcopenia due
to the heterogeneity of older persons, the existing multiple
operative definitions, and diverse (sometimes contradicting)
assessment methodologies, common estimates indicate it as
5–13% in the 60–70-year-old age group and 11–50% in the
80-year and older age group [51]. Such figures are expected
to dramatically rise in the next future due to the progressive
aging of Western populations with a profound and negative
impact on public health. In fact, sarcopenia (one of the most
important geriatric syndromes) represents an important risk
factor for functional impairment [52], physical disability
[53, 54], falls [55], and frailty [56, 57].
Skeletal muscle is a tissue formed by multiple types
of fibers. Briefly, type I fibers are slow contracting and
use an oxidative metabolism. Diﬀerently, type II fibers are
fast contracting and mainly glycolytic. Sarcopenic muscle
mass reduction is primarily due to a loss of muscle fibers
particularly characterized by a preferential atrophy of type
II fibers. At the same time, a conversion of fast type II muscle
fibers into slow type I fibers (with resulting loss in muscle
power and decline in protein synthesis, especially of myosin
heavy chains) has been described [58–60]. Overall, these
changes lead to a smaller, slower contracting muscle with
resulting reduced capacity to adequately perform activities
of daily living. These anatomical modifications have been (at
least partly) attributed to the age-related increase of oxidative
damage. In fact, the skeletal muscle is the largest consumer of
oxygen in the body with muscle fibers continuously generat-
ing ROS (especially during the contractile activity). Studies
adopting muscle biopsies have confirmed that markers of
oxidative damage are particularly and locally elevated in
skeletal muscle of older adults [61–64], promoting the above-
mentioned inadequacy of the antioxidant system in prevent-
ing damages [32, 65]. Some components of the enzymatic
scavenger system, such as catalase, glutathione transferase,
and superoxide dismutase, are also significantly depressed in
elderly muscle. The consequent prooxidant status results in
the alteration of mitochondrial DNA and abnormalities in
the electron transport system, leading to reduced calcium
uptake by the sarcoplasmic reticulum [66], irreversible
damage of the cell, and its consequent death [67–69].
In the healthy muscle, proteins and amino acids are
ideally balanced between synthesis and breakdown. In the
elderly, this equilibrium is disrupted because of a lower syn-
thesis and an increased breakdown rate of myofibrillar and
mitochondrial proteins. Several endogenous and exogenous
factors may aﬀect the organism capacity to maintain the
protein homeostasis. For example, it has been hypothesized
that muscle declinemight be caused by the direct detrimental
eﬀects of the chronic low-grade inflammatory status of
advanced age. In this context, it cannot be ignored the close
relationship between inflammation and oxidative damage.
Interestingly, both inflammation (in particular through the
TNF-α pathway) and oxidative damage are major regula-
tor of cellular apoptosis and protein metabolism. At the
same time, the age-related muscle protein loss may also
macroscopically be caused by the frequent reduction of food
intake in elders. Older persons are particularly exposed to
the risk of (micro- and macronutrient) malnutrition that
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might also be related to endogenous (e.g., malabsorption,
edentulism) or exogenous (e.g., lack of social support, dis-
ability) causes. Consequently, antioxidant supplementation
represents a promising intervention potentially able to
correct the inadequate diet of older persons and prevent the
skeletal muscle decline by inhibiting the vicious cycle at the
basis of protein catabolism.
Antioxidant supplementation may not replace the age-
related decline of the more complex antioxidant enzymatic
system. Nevertheless, in theory, by reinforcing the antiox-
idant nonenzymatic defences, supplementation might still
be helpful in preventing the onset of age-related conditions
(including sarcopenia) by acting on the same cause (i.e.,
oxidation). However, further studies are needed to better
understand the relationship between nonenzymatic and
enzymatic antioxidant defenses. In particular, it could be
that the two components are not parallel and indepen-
dent, but indeed synergistically constitute the antioxidant
system. Interestingly, Selman and colleagues [70] recently
demonstrated that vitamin C supplementation in mice is
associated with a downregulation of antioxidant protection
genes (including MnSOD).
5. Antioxidant Supplementation
and Sarcopenia
Despite the clinical relevance of sarcopenia and the large
interest for antioxidant supplementation (both from a
research and commercial standpoint of view), evidence in
this field is extremely limited and controversial. Most of the
studies available in the literature are from epidemiological
data with most even coming from cross-sectional observa-
tions.
The absence of a unique operative definition of sar-
copenia represents a major issue limiting the conduction of
research on the topic. In fact, most of the human studies
analyze the relationship between dietary antioxidant sup-
plementation and physical performance or muscle strength
measures, without specifically focusing on the broader
condition of sarcopenia. In fact, the quantitative (i.e., muscle
mass) and qualitative (i.e., muscle strength, muscle function)
declines follow separate and diﬀerent trajectories with aging.
The need of combining them into one single bidimensional
definition of sarcopenia is critical from a theoretical and
methodological perspective and has to be taken into account
when specifically facing the topic sarcopenia. In other words,
the separate evaluation of muscle mass or muscle strength
may significantly aﬀect the study of sarcopenia (limiting
its exploration to only one of the two components) and
likely result in biased findings. To our knowledge, there
are currently no trials verifying the eﬀects of antioxidant
supplementation on sarcopenia (as identified by one of
several the consensus definitions provided by international
groups of experts). Interestingly, a recent statement from the
Society on Sarcopenia, Cachexia, and Wasting Disease does
not even mention antioxidant supplementation as a possible
tool to manage sarcopenia in older persons [71].
Several studies have been conducted to evaluate the
eﬀects of antioxidant supplementation on antioxidant status
[72, 73]. Overall, results consistently report significant
improvements of antioxidant biomarkers after a period of
specific supplementation.
Diﬀerently, the eﬀect of antioxidant supplementation
on muscle performance is still and largely controversial.
Here are just a few examples of positive studies (from
both animal and human models) among the large body
of literature suggesting a beneficial eﬀect of antioxidant
supplementation and sarcopenia. Jakeman and Maxwell [74]
showed a protective eﬀect of vitamin C supplementation
against exercise-induced muscle damage. Similarly, Shafat
and colleagues [75] reported a reduction of muscle damage
by adopting a counteracting vitamin E and C supplementa-
tion. An antioxidant mixture containing vitamin E, vitamin
A, rutin, zinc, selenium has shown to increase the anabolic
response of old muscle to leucine and the leucine-induced
inhibition of protein degradation in rats [76]. Resveratrol,
a natural polyphenol found in grapes, peanuts, and berries
[77], has shown a protective eﬀect against oxidative stress
in skeletal muscle through the expression of antioxidant
enzymes [78]. At the same time, a similar (possibly larger)
number of studies have reported negative results on the topic.
For example, some trials have reported that antioxidant
supplementation may even be unfavorable on physical
performance and underlying biological mechanisms [79, 80].
A decrease of baseline levels of antioxidant mitochondrial
enzymes was reported by Strobel and colleagues [81] after
14 weeks of vitamin E and α-lipoic acid administration in
rats. Data by Ristow and colleagues [82] suggested that oral
administration of ascorbic acid and α-tocopherol prevents
exercise training-induced increases in insulin sensitivity and
ROS defense capacity. Consistently, the work by Higashida
and colleagues [83] showed no inhibitory eﬀect on the
adaptive responses of muscle to exercise by antioxidant
vitamin supplementation. Several studies [84–86] showed no
eﬀects of antioxidants supplementation on muscle function
after exercise-induced muscle damage. In a recent work,
Theodorou and colleagues [87] found that a supplementa-
tion with ascorbic acid and tocopherol does not aﬀect muscle
performance. Kondratov and colleagues [88] investigated
possible improvements of signs of premature aging (e.g.,
cataracts, cornea inflammation, joint ossification, and mus-
cle waste) in BMAL1 knockout mice by supplementation of
N-acetyl-L-cysteine (NAC), a low-molecular-weight antiox-
idant. Result suggested an extended lifespan, but excluded
significant eﬀects on sarcopenia. Sacheck et al. [89] showed
α-tocopherol supplementation in older fit men did not
suppress postexercise elevations in biomarkers of muscle
damage and lipid peroxidation such as in younger men.
More recently, vitamin E and C supplementation have shown
to reduce muscular levels of oxidative stress in repetitively
loaded muscles of old rats, but no increase in muscle mass
and maximal force production (after more than 4 weeks of
training) was found [90]. Consistent results were obtained by
Barker and colleagues [91] after administration of vitamin E
and C in men undergoing anterior cruciate ligament surgical
repair. It might seem that the biological eﬀects of antioxidant
supplementations are easily captured as increased levels of
antioxidant biomarkers. Diﬀerently, the clinically relevant
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and beneficial eﬀects of antioxidant supplementation are
more diﬃcult to be obtained (always if obtainable!).
Possible reasons for these controversial results are vari-
ous. First of all, it is possible that sarcopenia is not related
to oxidative damage, so that the obtained negative results are
indeed “true negative” findings. Second, it is not automatic
that the modification of a biomarker concentrations is able
to parallely change clinical parameters. It is more likely
that subclinical eﬀects are more sensible to changes than
clinically evident manifestations. And this is particularly true
when testing interventions in an extremely complex field
as geriatric syndromes, in which one sign/symptom is not
necessarily indicative of a well-defined condition. Diﬀerent
types and doses of antioxidants administered, timing of
supplementation, the adopted animal species, and the mea-
sured biomarkers may represent other important causes of
the negative findings. As mentioned, the heterogeneity and
methodological limitations aﬀecting the study of sarcopenia
may further explain the controversial findings.
Finally, it is noteworthy the extreme scarcity of available
clinical trials in humans on this topic. In fact, most of the
positive results are obtained in animal models and still wait
to be confirmed in humans. Furthermore, recent studies [92]
reporting possible negative eﬀects (e.g., cardiovascular and
all-cause mortality) of long-term, high-dosage antioxidant
supplementation (in particular, for vitamin E) cannot be
ignored.
In the present paper, we chose not to go into many
details about posologies of antioxidant supplementations.
Current literature on the topic is extremely heterogeneous
for methodological approaches, study designs (i.e., in vivo,
in vitro, epidemiological evaluations, clinical trials, animal or
human models), interventions (single antioxidant molecules
or in combination, timing of administration, posologies),
and outcome measures (i.e., biomarkers of muscle decline).
Such heterogeneity is not surprising considering the relative
novelty of the topic. After all, sarcopenia is a condition
theoretically defined only about 20 years ago, but its
operative definition is still debated.
6. Conclusion
In summary, there is some evidence that oral antioxidant
supplementation may reduce muscle damage, but experi-
mental results are largely preliminary and far to be clinically
relevant, at least, as suggestive of positive benefits. In fact, a
large body of evidence may indicate extreme cautiousness in
taking antioxidant supplementation as preventive measures
against aging process and age-related conditions. Further
studies are needed to support the widespread practice of oral
antioxidant supplementation and to determine appropriate
recommendations in elderly.
Although antioxidant supplementation through diet is
receiving growing attention, supporting evidence is still
scarce and equivocal. Antioxidant supplementation could
benefit muscle protein metabolism during aging, but fur-
ther trials in humans and with adequate sample sizes are
required to clearly establish the hypothesized relationship
between antioxidants and sarcopenia. In this context, a better
understanding of oxidation mechanisms, timing and doses
of antioxidant supplementation, and appropriate method-
ological approaches to study this theme is needed to provide
convincing evidence and justify the current widespread use
of antioxidants supplementation.
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